Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
NCT ID: NCT03244072
Last Updated: 2025-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2/PHASE3
60000 participants
INTERVENTIONAL
2026-06-01
2031-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.
NCT02770729
Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis
NCT02595359
Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis
NCT05079854
Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery
NCT05428683
Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery
NCT00331084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
Intracameral injection of moxifloxacin solution after cataract surgery
Moxifloxacin
Intracameral injection
Placebo group
Intracameral injection of placebo after cataract surgery
Placebo
intracameral injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moxifloxacin
Intracameral injection
Placebo
intracameral injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jason Ahee, M.D.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jason Ahee, M.D.
Medical Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason Ahee, M.D.
Role: PRINCIPAL_INVESTIGATOR
Zion Therapeutics, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zion Eye Institute
St. George, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jason Ahee, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PIND 134134
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.